Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Sell
50
MIST Quote, Financials, Valuation and Earnings
Last price:
$1.33
Seasonality move
:
3.7%
Day range:
$1.22 - $1.35
52-week range:
$0.63 - $2.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.99x
Volume:
1.9M
Avg. volume:
3.8M
1-year change:
-21.66%
Market cap:
$65.6M
Revenue:
$1M
EPS (TTM):
-$0.68
Analysts' Opinion
-
Consensus RatingMilestone Pharmaceuticals has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.00, Milestone Pharmaceuticals has an estimated upside of 306.5% from its current price of $1.23.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $1.23.
Fair Value
-
According to the consensus of 2 analysts, Milestone Pharmaceuticals has 306.5% upside to fair value with a price target of $5.00 per share.
MIST vs. S&P 500
-
Over the past 5 trading days, Milestone Pharmaceuticals has overperformed the S&P 500 by 14.45% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Milestone Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Milestone Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Milestone Pharmaceuticals reported revenues of --.
Earnings Growth
-
Milestone Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Milestone Pharmaceuticals reported earnings per share of -$0.19.
Enterprise value:
49.3M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
-1.71x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$59.6M | -$61.1M | -$42.1M | -$13.8M | -$12.3M | |
| EBITDA | -$58.3M | -$57M | -$37.8M | -$12.7M | -$11.4M | |
| Diluted EPS | -$1.37 | -$1.39 | -$0.68 | -$0.32 | -$0.19 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $148.7M | $118.9M | $71.8M | $73M | $73.9M | |
| Total Assets | $150M | $119.8M | $74.5M | $75.2M | $75.5M | |
| Current Liabilities | $6.2M | $6.8M | $6.1M | $7.2M | $8.1M | |
| Total Liabilities | $6.9M | $7.2M | $8.1M | $58.5M | $62.4M | |
| Total Equity | $143.1M | $112.6M | $66.3M | $16.8M | $13.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$52.5M | -$46.4M | -$28.8M | -$9.8M | -$6.8M | |
| Cash From Investing | -$57.1M | $4.8M | $8.3M | $13.7M | $19.3M | |
| Cash From Financing | $3.1M | $47.8M | $32.1M | $1K | $24K | |
| Free Cash Flow | -$52.7M | -$46.5M | -$28.9M | -$9.8M | -$6.9M | |
MIST
Sector
Market Cap
$65.6M
$34.9M
Price % of 52-Week High
44.73%
44.35%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
-21.66%
-38.5%
Beta (5-Year)
1.381
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.15
200-day SMA
Sell
Level
$1.64
Bollinger Bands (100)
Sell
Level
1.27 - 2.25
Chaikin Money Flow
Sell
Level
-10.5M
20-day SMA
Buy
Level
$0.92
Relative Strength Index (RSI14)
Buy
Level
51.45
ADX Line
Buy
Level
20.15
Williams %R
Sell
Level
-18.9189
50-day SMA
Sell
Level
$1.51
MACD (12, 26)
Sell
Level
-0.07
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Neutral
Level
167.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.9368)
Sell
CA Score
(Annual)
Level (-3.6479)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (5.8973)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Stock Forecast FAQ
In the current month, MIST has received 0 Buy ratings 2 Hold ratings, and 0 Sell ratings. The MIST average analyst price target in the past 3 months is $5.00.
-
Where Will Milestone Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Milestone Pharmaceuticals share price will rise to $5.00 per share over the next 12 months.
-
What Do Analysts Say About Milestone Pharmaceuticals?
Analysts are divided on their view about Milestone Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Milestone Pharmaceuticals is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Milestone Pharmaceuticals's Price Target?
The price target for Milestone Pharmaceuticals over the next 1-year time period is forecast to be $5.00 according to 2 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is MIST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Milestone Pharmaceuticals is a Hold. 2 of 2 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of MIST?
You can purchase shares of Milestone Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Milestone Pharmaceuticals shares.
-
What Is The Milestone Pharmaceuticals Share Price Today?
Milestone Pharmaceuticals was last trading at $1.33 per share. This represents the most recent stock quote for Milestone Pharmaceuticals. Yesterday, Milestone Pharmaceuticals closed at $1.23 per share.
-
How To Buy Milestone Pharmaceuticals Stock Online?
In order to purchase Milestone Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 5.48% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 1.82% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 3.3% over the past day.
